-
The multinational pharmaceutical company has approved the listing of a number of new drugs in China
Time of Update: 2022-10-03
For example, recently, the website of the Drug Evaluation Center (CDE) of the State Food and Drug Administration showed that the application for the listing of Pfizer JAK3 inhibitor litecotinib capsules was accepted for the treatment of adolescents aged 12 and over and adults alopecia areata.
-
This pharmaceutical company has blossomed in the field of new oncology drugs, and another new drug has been approved clinically!
Time of Update: 2022-10-02
It is worth noting that in addition to SHR-A2102 injection, Hengrui Pharmaceutical recently issued an announcement that it received the "Drug Clinical Trial Approval Notice" approved by the State Food and Drug Administration on HRS-6209 capsules, and will carry out clinical trials in the near future.
-
This pharmaceutical machine company has been investigated by the institution, and the company's products have a strong competitive advantage
Time of Update: 2022-10-02
According to reports, the main business of Tailin Biology is the research and development, manufacturing and sales of pharmaceutical equipment such as microbial detection and control technology system products and organic matter analysis instruments.
-
In order to be more streamlined, Novartis plans to lay off thousands more people and close some factories
Time of Update: 2022-10-01
Since the beginning of this year, Novartis, a leading multinational pharmaceutical company, has made continuous moves, first announcing the adjustment of the company's global business framework, planning to lay off 8,000 employees, and then integrating the two business units of pharmaceuticals and oncology into one innovative drug department, while merging the technology operations, customers and technical departments.
-
Today, another new pharmaceutical stock will be listed on the GEM!
Time of Update: 2022-10-01
It is worth mentioning that in addition to the external lotion of gynecology, Enwei Pharmaceutical has not disconnected the dosage forms such as ointments, suppositories, effervescent tablets and disinfection products such as bacteriostatic lotion, and intends to develop gynecological internal medicine series products in independent research and development, joint research and development, purchase of varieties and other ways, and constantly maintain and further enhance the company's advantages in the field of domestic gynecological products.
-
In the first half of the year, domestic pharmaceutical companies with R&D investment of more than 1 billion yuan have a variety of potential first-in-class
Time of Update: 2022-10-01
According to reports, JS004 is the world's first recombinant humanized anti-BTLA monoclonal antibody specifically targeting B and T lymphocyte attenuation factor (BTLA) that has entered the clinical development stage of the company's independent research and development.
-
In the 100 billion market, this pharmaceutical company with a large number of new drugs is accelerating the grabbing of food
Time of Update: 2022-09-30
In fact, in recent years, Yangtze River Pharmaceutical and its subsidiaries are still increasing the research and development of nervous system drugs, in addition to the advantages of pain relief, mental stability, local anesthesia, but also expanded to other subcategories.
-
Two chemical drugs have been approved one after another! The landing of pipeline products of the pharmaceutical company is gradually being cashed in
Time of Update: 2022-09-14
On September 6, Tasly announced that jiangsu Diyi, a wholly-owned subsidiary of the company, recently received the "Drug Registration Certificate" approved and issued by the State Drug Administration on bortezomib for injection.
-
This traditional Chinese medicine company issued 19 announcements in one day, related to the semi-annual report, the departure of executives, etc.
Time of Update: 2022-09-09
1576 million, and the financing balance decreased ; According to information from the Shenzhen Stock Exchange, on August 26, *ST Bikang issued 19 announcements in succession, which were related to the interim report performance and the resignation of executives .
-
Local pharmaceutical companies have expanded production capacity, and this company has broken restrictions to double its revenue
Time of Update: 2022-09-09
Judging from the commercialized product line, up to now, Henlius has a total of 5 products approved for marketing, namely rituximab (Hanlikang), trastuzumab (Hanquyou), adalimumab Monoclonal antibody (Handayuan), bevacizumab (Hambetai) 4 biosimilars, and innovative drug PD-1 inhibitor slulimumab (Hans-shaped) .
-
In order to enhance competitiveness, this traditional Chinese medicine formula granule company has increased capital and shares!
Time of Update: 2022-09-09
For example, on June 29 this year, Yibai Pharmaceutical announced that, by consensus, the company plans to jointly increase the capital of Yibai Formula Granules, a wholly-owned subsidiary of the company, with the Guizhou Agricultural Development Fund to invest in the construction of the company's entire industry chain project of traditional Chinese medicine formula granules .
-
The pharmaceutical company's innovative drugs have reported good news one after another. In the first half of the year, the company's R&D investment increased by 22.77% year-on-year.
Time of Update: 2022-09-08
On the evening of August 26, Fosun Pharma announced that its holding subsidiary Fuhong Henlius’ HLX60 (recombinant anti-GARP humanized monoclonal antibody injection) combined with slulimumab injection (Hans-shaped) was used for Advanced/metastatic solid tumor therapy approved for clinical trials in Australia .
-
This pharmaceutical company plans to buy technology for 20 million yuan and accelerate the pace of entering the field of nuclear medicine
Time of Update: 2022-09-06
On September 2, Yunnan Baiyao announced that the company signed a "Technology Transfer and Cooperative Development Agreement" with Peking University Hospital and Bei Tuo Research Institute, and planned to obtain 20 million yuan for the prostate-specific membrane antigen (PSMA) targeting nucleus jointly developed by the latter.
-
The medical beauty business is booming!
Time of Update: 2022-08-20
Sinolink Securities stated in the research report that the official listing of Huadong Medicine's optoelectronic medical beauty device "Ku Xue" is expected to drive the improvement of annual performance .
-
Huadong Medicine spends 396 million yuan to increase the layout of the nucleoside field
Time of Update: 2022-08-20
Recently, Huadong Medicine announced that it will invest no more than 396 million yuan to obtain a 60% stake in Wuhu Huaren Technology Co. , Ltd. (hereinafter referred to as "Huaren Technology") and b
-
The gene technology market has broad prospects, and leading companies plan to build a base of 1.65 billion
Time of Update: 2022-08-20
65 billion yuan to invest in the construction of the Huada Gene headquarters base project in the joint bid for the joint bid of J402-0349 in Yantian District .
-
220 million yuan!
Time of Update: 2022-08-20
According to the data, as of the first half of 2022, there were 2,426 applications for the transfer of drug approval documents nationwide, of which 1,338 were for traditional Chinese medicines, accounting for 55.
-
The first exhibition of resumption of work in July is ready to go, and more than 5,000 people in the biopharmaceutical circle have pre-registered
Time of Update: 2022-08-11
July Hangbo | The first exhibition of resumption of work is ready to go: 200+ heavyweight speakers, more than 5,000 people in the biopharmaceutical circle have pre-registered! The 9th International Bi
-
From nervousness to calmness
Time of Update: 2022-08-11
Reliability, including its successful flight, lays a good foundation It is easy for the chief designer of the Long March 2 F rocket of the Aerospace Science and Technology Group: when the seniors were developing and tackling key problems at that time, there were not only the hardships in the tackling process, but also all aspects of the living environment.
-
The details of the specific reasons for the investigation of 3 nucleic acid testing institutions in Beijing within 10 days have been exposed!
Time of Update: 2022-08-11
At present, criminal compulsory measures have been taken against six people On the afternoon of May 21, the Beijing Municipal Public Security Bureau announced on its official Weibo account that the police had filed a case for investigation of the crime of obstructing the prevention and treatment of infectious diseases in relation to issues related to the Beijing Pu Shi Medical Laboratory.
